title: [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
abstract: Chronic administration of levodopa and benserazide (10 and 15 mg/kg, respectively) cause the development of dyskinesia in rats with model parkinsonian syndrome induced by injection of 6-hydroxydopamine in left substantia nigra. The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia. Chronic administration of levodopa and benserazide together with hemantane (10 mg/kg) slows down the development and decreases the magnitude of levodopa-induced abnormal involuntary movements as measured for limb, orolingual and rotatory movements.
authors: I G
authors: IG
authors: Kapitsa
authors: E A
authors: EA
authors: Ivanova
authors: A V
authors: AV
authors: Nepoklonov
authors: I I
authors: II
authors: Kokshenev
authors: T A
authors: TA
authors: Voronina
authors: E A
authors: EA
authors: Val'dman
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001545:Benserazide / Q000494:pharmacology; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D016627:Oxidopamine / Q000008:administration & dosage / Q000009:adverse effects; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects*
chemical_list: C526127:hemantane; D007980:Levodopa; D001545:Benserazide; D016627:Oxidopamine; D000547:Amantadine; D000218:Adamantane